Do you think our company will make another year?

yawn...yawn.

 

Thought this deserved to be at the top again. So all can see who started this BS!

 

OMG.

 

Looks like te shorts lst this battle from a few year ago

 

Paying off docs-, selling an overpriced drug that has studies from 1970. Company won't do studies in fear that it won't even be as good as generic cheap steroids! Truly to most unethical scamming the system money hungry company I've ever worked for. I had a hard time raising my 2 kids to be honest and ethical and teaching them money isn't everything and not feeling like I'm doing that every day when I wake up and go to work. I will be gone soon to a better more stable company and finally be able to sleep at night!

 

LMFAO. Getting all upset because you have to pimp out your wife and kids to pay for your short? What a hypocrite

 

That is some funny sh1t right there. Shorties got there a$$es handed to them big time on this one.

 

And cephalon pukes

 

http://www.cnbcprime.com/american-greed/

 

Share on StockTwits

Questcor Pharmaceuticals logoQuestcor Pharmaceuticals (NASDAQ:QCOR) Insider Don M. Bailey unloaded 40,000 shares of Questcor Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $91.96, for a total transaction of $3,678,400.00. Following the transaction, the insider now directly owns 140,437 shares in the company, valued at approximately $12,914,587. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Questcor Pharmaceuticals (NASDAQ:QCOR) remained flat at $93.60 during trading on Friday. Questcor Pharmaceuticals has a 1-year low of $47.71 and a 1-year high of $97.80. The stock’s 50-day moving average is $92.90 and its 200-day moving average is $81.15. The company has a market cap of $5.587 billion and a price-to-earnings ratio of 16.41.

Questcor Pharmaceuticals (NASDAQ:QCOR) last posted its quarterly earnings results on Thursday, July 24th. The company reported $1.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.11. The company had revenue of $278.80 million for the quarter, compared to the consensus estimate of $261.02 million. During the same quarter in the previous year, the company posted $1.12 earnings per share. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, analysts predict that Questcor Pharmaceuticals will post $6.73 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Oppenheimer downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, July 25th. They now have a $86.00 price target on the stock. Analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $84.44.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company

 

So your point is, what exactly?

 

Oh please. Get off your soapbox. You've had no problems working here for years and now you throw the ethics card out? Give us a break as you try to come up with a reason to tell employers "why you are moving on". You had no problem accepting the pay checks for how long?

 

No soap box, just stating the facts..

 

Then quit

 

Or stay & ride the pony all the way to the finish line!